Related Experiment Video
Updated: Nov 4, 2025

05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
4.1K
Differences in Levodopa Response for Progressive and Non-Progressive Micrographia in Parkinson's Disease
Poonam Zham1,2, Sridhar A Poosapadi1,3, Peter Kempster4,5
1School of Engineering, RMIT University, Melbourne, VIC, Australia.
Frontiers in Neurology
|May 28, 2021
Summary
Progressive micrographia in Parkinson's disease (PD) shows less improvement with levodopa treatment compared to non-progressive micrographia. Kinematic analysis reveals distinct drug responses for these PD subtypes.
Area of Science:
- Neurology
- Movement Disorders
- Pharmacology
Background:
- Micrographia is a common writing impairment in Parkinson's disease (PD).
- It can be classified as progressive (with a decremental pattern) or non-progressive.
- The kinematic response of progressive micrographia to levodopa is not well understood.
Purpose of the Study:
- To investigate and compare the kinematic response to levodopa in progressive micrographia (PD_PM) versus non-progressive micrographia (PD_NPM) in Parkinson's disease patients.
Main Methods:
- Twenty-four PD patients performed repeated writing tasks on a digital tablet in both an 'off' state and after levodopa administration.
- Scripts were analyzed to classify patients into PD_PM or PD_NPM based on a 10% decrement in writing features.
- Levodopa's effect was assessed using MDS-UPDRS motor scores and kinematic writing parameters.
Main Results:
- Levodopa improved writing speed in both PD_PM and PD_NPM groups, but the improvement was more than twofold greater in the PD_NPM group.
- Key decremental features (size, speed, pen pressure) in PD_PM were largely unaffected by levodopa.
- Both groups showed similar motor improvements on the MDS-UPDRS scale.
Conclusions:
- Progressive micrographia exhibits reduced responsiveness to levodopa compared to non-progressive micrographia.
- These findings suggest that the sequence effect in PD bradykinesia may be relatively resistant to levodopa.
- Careful interpretation of micrographia measurements is advised when assessing drug efficacy in PD.
Related Concept Videos
Parkinson's Disease: Treatment
623
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
623
Parkinson's Disease: Overview
1.0K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.0K
Neural Regulation
40.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.8K

